Trial Profile
Investigation of the single ascending dose tolerability, PK and PD of ACT-064992 in healthy male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2014
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Eisenmenger complex; Glioblastoma; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Skin ulcer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Actelion Pharmaceuticals
- 14 Aug 2014 New trial record